Cytocell Ltd Introduces New ROS1 Genetic Test for Non-Small-Cell Lung Cancer

AsiaNet 50872

CAMBRIDGE, England, Oct. 2, 2012 /PRN=KYODO JBN/ --

    Cytocell Ltd. today announced the availability of a new molecular

cytogenetic test designed to identify the presence of gene rearrangements

associated with a specific form of non-small-cell lung cancer (NSCLC). These

rearrangements in a gene known as ROS1 (c-ros oncogene 1) have been implicated

in the formation of cancerous tumors in patients with NSCLC.

    (Logo: http://photos.prnewswire.com/prnh/20120906/559436 )

    Lung cancer is the world's leading cause of cancer death with more than 1.6

million new cases diagnosed each year. About 85 percent of lung cancer patients

have the non-small-cell type and are usually diagnosed with advanced disease

with a very low survival rate. ALK gene rearrangements have been shown to

respond to therapies that block the ALK pathway. Over 2 percent of those

patients are thought to have ROS1 gene rearrangements and have been shown to

respond to ALK/MET tyrosine kinase inhibitors such as Xalkori(R)(crizotinib).

The Cytocell ROS1 Breakapart FISH probe uses Fluorescence In Situ Hybridization

(FISH) technology to detect rearrangements of the ROS1 gene on chromosome 6 in

band 6q22 in tumors. The new Cytocell assay will complement the existing

Cytocell Pathology range which also includes the equally important ALK

Breakapart FISH probe. It is anticipated that both FISH probes will be used for

research, testing, and to support evaluations of new therapies for NSCLC.

    Dr Martin Lawrie, Managing Director of Cytocell stated, "Understanding the

mechanisms of lung cancer and developing new tests that further increase our

knowledge are key to our strategic focus at Cytocell. Through the utilisation

of Cytocell's BACs collection and the myProbes(R) customised probe service we

were firstly able to offer this probe to several key researchers before

launching it as a catalogue item."

    About Cytocell Ltd.

    Cytocell is a leading European developer and manufacturer of FISH probes

for use in both routine cytogenetics and in the analysis and classification of

Cancers. The Company's products are well established in Cytogenetics as the

Company is celebrating its 20th year of supplying them to this market. More

recently, the Company has focused on developing products for Oncology and now

has a catalogue of some 350 products for Cytogenetics, Haematology and Solid

Tumour analysis as well as developing custom FISH probes for customers with

specific interests under the myProbes(R) brand. Cytocell's products are

available through a well established distributor network, covering more than 60

countries worldwide. Cytocell's FISH probe service is currently proving to be

invaluable to cancer researchers and clinicians worldwide.

    Cytocell's news releases and other information are available on the

company's Web site at http://www.cytocell.com.

    For further enquiries, please contact:

    Stewart Kennedy,

    Tel: +44-7860-455527

    Sales & Marketing Director

    SOURCE: Cytocell Ltd